Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis.
Antimicrob Agents Chemother
; 63(8)2019 08.
Article
em En
| MEDLINE
| ID: mdl-31160289
ABSTRACT
There is an urgent need for novel therapeutics to treat Mycobacterium tuberculosis infections. Genetic strategies for validating novel targets are available, yet their time-consuming nature limits their utility. Here, using MmpL3 as a model target, we report on the application of mycobacterial CRISPR interference for the rapid validation of target essentiality and compound mode of action. This strategy has the potential to rapidly accelerate tuberculosis drug discovery.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteínas de Membrana Transportadoras
/
Proteínas de Bactérias
/
Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas
/
Mycobacterium tuberculosis
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article